The Use of Topical Ruxolitinib 1.5% Cream in Frontal Fibrosing Alopecia: A Case Report

This case report highlights the potential efficacy of topical ruxolitinib 1.5% cream in treating frontal fibrosing alopecia (FFA), a condition with limited treatment options. A 55-year-old male patient with FFA, unresponsive to conventional therapies, experienced stabilization of the frontal hairline, resolution of physical symptoms, and clearance of facial papules after applying the cream generously for 3 months. The report suggests that topical ruxolitinib, a JAK inhibitor, may offer a favorable safety profile and fewer side effects compared to oral JAK inhibitors. However, the high cost and insurance coverage challenges remain significant barriers to access. The authors advocate for broader insurance coverage to improve patient access to this promising treatment.